| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Solid Biosciences Inc.
13D/A
Amendment 11
SLDB · 83422E105
|
8.8% |
3/10/2026
Event 3/6/2026
|
|||
| BCLS SB Investco, LP | 0% | ||||
| Bain Capital Life Sciences Fund II, L.P. | 0.3% | ||||
| BCLS II Investco, LP | 8.8% | ||||
| BCIP Life Sciences Associates, LP | 0.1% | ||||
| BCLS II Equity Opportunities, LP | 1.0% | ||||
| Bain Capital Life Sciences Opportunities IV, L.P. | 5.4% | ||||
|
Solid Biosciences Inc.
13D/A
Amendment 10
SLDB · 83422E105
|
7.8% |
2/21/2025
Event 2/19/2025
|
|||
| BCLS SB Investco, LP | 0.7% | ||||
| Bain Capital Life Sciences Fund II, L.P. | 0.3% | ||||
| BCLS II Investco, LP | 7.8% | ||||
| BCIP Life Sciences Associates, LP | <0.1% | ||||
| BCLS II Equity Opportunities, LP | 1.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.